US stock futures (ES=F, NQ=F, YM=F) are surging Monday morning after US and China officials agreed to significant cuts to each country's respective tariff rates in a 90-day cool-off period. April's Consumer Price Index (CPI) is due out tomorrow, reporting month-over-month trends in US inflation rates. President Trump vows to cut prescription drug prices by as much as 80%. In turn, pharmaceutical stocks are seeing across the board pullbacks in pre-market trading. To watch more expert insights and analysis on the latest market action, check out more Morning Brief here. Video Transcript 00:00 Brad Smith Welcome to Yahoo Finance's flagship show, The Morning Brief. I'm Brad Smith, alongside Madison Mills. Let's get to the three things you need to know. 00:06 Madison Mills First up, US stocks soaring today as investors cheer the trade deal between the US and China. The US will cut the tariff rate on Chinese goods to 30%, and China will cut US tariffs to 10% for a 90-day period. Temporary truce sending stocks on a tear with all magnificent seven members moving sharply higher. Across asset classes, the dollar is also moving to the upside. Meantime, treasuries and gold taking a bit of a tumble. 00:32 Brad Smith Plus, investors also awaiting the April inflation report, which will show the immediate impacts of the liberation day tariffs. CPI categories that are China import intensive, such as toys, shoes, and apparel may see some modest inflation. But overall, the CPI report is expected to come in closer to the Federal Reserve's 2% target. 00:50 Madison Mills And pharmaceutical stocks taking a hit today as President Trump says he plans to order a cut in prescription drug costs that could go as high as 80%. A potential decrease in prescription drug prices could have a significant impact on the industry's profits, particularly for companies that depend heavily on US sales. Could face lawsuits and resistance from the industry and lawmakers. President will sign the executive order this morning. Related Videos 20:46 Why US-China tariff agreement isn’t super bullish for stocks Yahoo Finance Video • 1 hour ago 03:51 US, China Deal Removes Some Risk From Markets, Slok Says Bloomberg • 1 hour ago 01:46 One top bond strategist's 'best spot' to invest Yahoo Finance Video • 3 hours ago 04:10 US-China Cool-Off Adds to Positive Sentiment, BlackRock Says Bloomberg • 4 hours ago View Comments
US-China trade truce, April CPI, drug prices: 3 Things
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...